Hamilton Thorne (TSE:HTL) has released an update.
Hamilton Thorne Ltd. has reported a robust first quarter for 2024 with a 16% increase in sales to $19.4 million and a 24% rise in Adjusted EBITDA to $3.5 million, showcasing strong financial performance and adherence to their annual guidance. The company observed a significant improvement in gross profit margin to 52.4% and confirmed their full-year sales forecast, indicating a 10-15% organic growth. These results reflect a solid demand for Hamilton Thorne’s products in IVF/ART clinics and laboratories worldwide.
For further insights into TSE:HTL stock, check out TipRanks’ Stock Analysis page.
